Adaptive Phage Therapeutics (APT) is developing PhageBank, a collection of viruses to kill antibiotic-resistant superbugs. They needed a highly agile vial filling system and chose the Microcell™ Vial Filler to accelerate the process of filling multiple viruses every day to build a library of 1000+ drug products.
Moderna is using an SA25 Aseptic Filling Workcell from Cytiva at its Norwood, Massachusetts site for both clinical trial supply manufacturing and product development.
Gaining control for gene-edited therapies
Locus Biosciences is taking the fight against antibiotic-resistant bacteria using CRISPR-Cas3 gene-edited therapies. They chose the Microcell™ Vial Filler to gain control over their processes.